breast cancer research and treatment editorial board

Submission guidelines

Types of paper, manuscript submission, statements & declarations, artwork and illustrations guidelines, supplementary information (si), research data policy and data availability statements, after acceptance.

Open Choice

Ethical Responsibilities of Authors

Authorship principles, compliance with ethical standards, disclosure of potential conflicts of interest, research involving human participants, their data or biological material, informed consent, editing services, open access publishing.

• Mistakes to avoid during manuscript preparation

Instructions for Authors

The journal publishes original laboratory investigations, clinical and translational studies. It also hosts reviews, editorials, and letters.

The length of submitted papers should not exceed 3500 words. Word count does not include abstract, title page, tables and figures or references.

Submissions of review and meta-analyses papers require pre-approval by the Editor.

Note: Authors must suggest at least three possible reviewers without conflict of interest in the Cover Letter upon submission. Authors are highly recommended to provide academic email addresses instead of personal ones.

Letter to the Editor

Manuscript body text is limited to 750 words. There is no abstract. There may be 1 figure, up to 3 references, and no more than 3 authors, with author affiliations only including main institution, place name and (state plus) country (i.e. no departments, etc.).

Tumor Marker Studies

Manuscript describing the results of tumor marker studies should include the essential elements of "Reporting recommendations for tumor marker prognostic studies (REMARK)" (McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235).

Failure to do so will result in the manuscript being returned to the author without peer review, as outlined by the editors of Breast Cancer Research and Treatment : Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100(2):237-238). J Clin Oncol. 2005 23:9067-9072.

Cell Line Studies

In general, Breast Cancer Research and Treatment will not accept for publication papers in which all of the data shown in the paper were obtained using a single cell line. Indeed, for most studies, experiments involving the use of multiple cell lines (more than 2) is highly recommended. In rare exceptions 'single cell line' papers will be considered but only when the use of a single line was necessitated by the scope of the other experiments, such as those involving screens of thousands of shRNAs or compounds. When submitting a paper in which all reported data were obtained with a single cell line, the authors must justifiy why one cell line was used, or the paper will be returned without review.

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit manuscript” and upload all of your manuscript files following the instructions given on the screen.

Source Files

Please ensure you provide all relevant editable source files at every submission and revision. Failing to submit a complete set of editable source files will result in your article not being considered for review. For your manuscript text please always submit in common word processing formats such as .docx or LaTeX.

Submitting Declarations

Please note that Author Contribution information and Competing Interest information must be provided at submission via the submission interface. Only the information submitted via the interface will be used in the final published version. Please make sure that if you are an editorial board member and also a listed author that you also declare this information in the Competing Interest section of the interface.

Please see the relevant sections in the submission guidelines for further information on these statements as well as possible other mandatory statements.

This publication requires that the corresponding author provides his/her ORCiD ID before proceeding with submission.

For more information about this journal’s ORCiD policy, please visit the ORCID FAQ

Please make sure your title page contains the following information.

The title should be concise and informative.

Author information

• The name(s) of the author(s)
• The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country
• A clear indication and an active e-mail address of the corresponding author
• If available, the 16-digit ORCID of the author(s)

If address information is provided with the affiliation(s) it will also be published.

For authors that are (temporarily) unaffiliated we will only capture their city and country of residence, not their e-mail address unless specifically requested.

Large Language Models (LLMs), such as ChatGPT , do not currently satisfy our authorship criteria . Notably an attribution of authorship carries with it accountability for the work, which cannot be effectively applied to LLMs. Use of an LLM should be properly documented in the Methods section (and if a Methods section is not available, in a suitable alternative part) of the manuscript. The use of an LLM (or other AI-tool) for "AI assisted copy editing" purposes does not need to be declared. In this context, we define the term "AI assisted copy editing" as AI-assisted improvements to human-generated texts for readability and style, and to ensure that the texts are free of errors in grammar, spelling, punctuation and tone. These AI-assisted improvements may include wording and formatting changes to the texts, but do not include generative editorial work and autonomous content creation. In all cases, there must be human accountability for the final version of the text and agreement from the authors that the edits reflect their original work.

Please provide a structured abstract of 150 to 250 words which should be divided into the following sections:

• Purpose (stating the main purposes and research question)

For life science journals only (when applicable)

• Trial registration number and date of registration for prospectively registered trials
• Trial registration number and date of registration followed by “retrospectively registered”, for retrospectively registered trials

Please provide 4 to 6 keywords which can be used for indexing purposes.

Text Formatting

Manuscripts should be submitted in Word.

• Use a normal, plain font (e.g., 10-point Times Roman) for text.
• Use italics for emphasis.
• Use the automatic page numbering function to number the pages.
• Do not use field functions.
• Use tab stops or other commands for indents, not the space bar.
• Use the table function, not spreadsheets, to make tables.
• Use the equation editor or MathType for equations.
• Note: If you use Word 2007, do not create the equations with the default equation editor but use the Microsoft equation editor or MathType instead.
• Save your file in doc format. Do not submit docx files.

Manuscripts with mathematical content can also be submitted in LaTeX.

LaTeX macro package (Download zip, 190 kB)

Please use no more than three levels of displayed headings.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter. A table of Abbreviations can be included following the Abstract.

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.

Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.

Always use footnotes instead of endnotes.

Acknowledgments and Funding Information

Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full. In addition, please provide the funding information in a separate step of the submission process in the peer review system. Funder names should preferably be selected from the standardized list you will see during submission. If the funding institution you need is not listed, it can be entered as free text. Funding information will be published as searchable metadata for the accepted article, whereas acknowledgements are published within the paper.

Reference citations in the text should be identified by numbers in square brackets. Some examples:

1. Negotiation research spans many disciplines [3].

2. This result was later contradicted by Becker and Seligman [5].

3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text.

The entries in the list should be numbered consecutively.

If available, please always include DOIs as full DOI links in your reference list (e.g. “https://doi.org/abc”).

Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L (2009) Effect of high intensity intermittent training on heart rate variability in prepubescent children. Eur J Appl Physiol 105:731-738. https://doi.org/10.1007/s00421-008-0955-8

Ideally, the names of all authors should be provided, but the usage of “et al” in long author lists will also be accepted:

Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J Med 965:325–329

Slifka MK, Whitton JL (2000) Clinical implications of dysregulated cytokine production. J Mol Med. https://doi.org/10.1007/s001090000086

South J, Blass B (2001) The future of modern genomics. Blackwell, London

Brown B, Aaron M (2001) The politics of nature. In: Smith J (ed) The rise of modern genomics, 3rd edn. Wiley, New York, pp 230-257

Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007

Trent JW (1975) Experimental acute renal failure. Dissertation, University of California

Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see

ISSN.org LTWA

If you are unsure, please use the full journal title.

Authors preparing their manuscript in LaTeX can use the bibliography style file sn-basic.bst which is included in the Springer Nature Article Template .

The following statements must be included in your submitted manuscript under the heading 'Statements and Declarations'. This should be placed after the References section. Please note that submissions that do not include required statements will be returned as incomplete.

Please describe any sources of funding that have supported the work. The statement should include details of any grants received (please give the name of the funding agency and grant number).

Example statements:

“This work was supported by […] (Grant numbers […] and […]). Author A.B. has received research support from Company A.”

“The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.”

Competing Interests

Authors are required to disclose financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work.

“Financial interests: Author A and B declare they have no financial interests. Author C has received speaker and consultant honoraria from Company M. Dr. C has received speaker honorarium and research funding from Company M and Company N. Author D has received travel support from Company O. Non-financial interests: Author D has served on advisory boards for Company M and Company N.”

“The authors have no relevant financial or non-financial interests to disclose.”

Please refer to the “Competing Interests” section below for more information on how to complete these sections.

Author Contributions

Authors are encouraged to include a statement that specifies the contribution of every author to the research and preparation of the manuscript.

Example statement:

“All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [full name], [full name] and [full name]. The first draft of the manuscript was written by [full name] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.”

Please refer to the “Authorship Principles ” section below for more information on how to complete this section.

Data Availability

All original research must include a Data Availability Statement. Data Availability Statements should provide information on where data supporting the results reported in the article can be found. Statements should include, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. When it is not possible to share research data publicly, for instance when individual privacy could be compromised, data availability should still be stated in the manuscript along with any conditions for access.

“The datasets generated during and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT LINK TO DATASETS]”

“The datasets generated during and/or analysed during the current study are not publicly available due to [REASON(S) WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.].”

Please refer to the “Research Data Policy and Data Availability” section below for more information on how to complete this section.

In addition to the above, manuscripts that report the results of studies involving humans and/or animals should include the following declarations:

Ethics approval

Authors of research involving human or animal subjects should include a statement that confirms that the study was approved (or granted exemption) by the appropriate institutional and/or national research ethics committee (including the name of the ethics committee and reference number, if available). For research involving animals, their data or biological material, authors should supply detailed information on the ethical treatment of their animals in their submission. If a study was granted exemption or did not require ethics approval, this should also be detailed in the manuscript.

“This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University B (Date.../No....).”

“This is an observational study. The XYZ Research Ethics Committee has confirmed that no ethical approval is required.”

For detailed information on relevant ethical standards and criteria, please refer to the sections on “Research involving human participants, their data or biological material”, “Research involving animals, their data or biological material”.

Consent to participate

For all research involving human subjects, freely-given, informed consent to participate in the study must be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript.

“Informed consent was obtained from all individual participants included in the study.”

“Written informed consent was obtained from the parents.”

Please refer to the section on “Informed Consent” for additional help with completing this information.

Consent to publish

Individuals may consent to participate in a study, but object to having their data published in a journal article. If your manuscript contains any individual person’s data in any form (including any individual details, images or videos), consent for publication must be obtained from that person, or in the case of children, their parent or legal guardian. This is in particular applicable to case studies. A statement confirming that consent to publish has been received from all participants should appear in the manuscript.

“The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1a, 1b and 1c.”

• All tables are to be numbered using Arabic numerals.
• Tables should always be cited in text in consecutive numerical order.
• For each table, please supply a table caption (title) explaining the components of the table.
• Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
• Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Electronic Figure Submission

• Supply all figures electronically.
• Indicate what graphics program was used to create the artwork.
• For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
• Vector graphics containing fonts must have the fonts embedded in the files.
• Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
• Definition: Black and white graphic with no shading.
• Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
• All lines should be at least 0.1 mm (0.3 pt) wide.
• Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.

Halftone Art

• Definition: Photographs, drawings, or paintings with fine shading, etc.
• If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
• Halftones should have a minimum resolution of 300 dpi.

Combination Art

• Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
• Combination artwork should have a minimum resolution of 600 dpi.
• Color art is free of charge for online publication.
• If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
• If the figures will be printed in black and white, do not refer to color in the captions.
• Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

• To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
• Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
• Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
• Avoid effects such as shading, outline letters, etc.
• Do not include titles or captions within your illustrations.

Figure Numbering

• All figures are to be numbered using Arabic numerals.
• Figures should always be cited in text in consecutive numerical order.
• Figure parts should be denoted by lowercase letters (a, b, c, etc.).
• If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,"A1, A2, A3, etc." Figures in online appendices [Supplementary Information (SI)] should, however, be numbered separately.

Figure Captions

• Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
• Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
• No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
• Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
• Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

• Figures should be submitted within the body of the text. Only if the file size of the manuscript causes problems in uploading it, the large figures should be submitted separately from the text.
• When preparing your figures, size figures to fit in the column width.
• For large-sized journals the figures should be 84 mm (for double-column text areas), or 174 mm (for single-column text areas) wide and not higher than 234 mm.
• For small-sized journals, the figures should be 119 mm wide and not higher than 195 mm.

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

• All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
• Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
• Any figure lettering has a contrast ratio of at least 4.5:1

Generative AI Images

Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein.

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.

Before submitting research datasets as Supplementary Information, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.

• Supply all supplementary material in standard file formats.
• Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
• To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
• High resolution (streamable quality) videos can be submitted up to a maximum of 25GB; low resolution videos should not be larger than 5GB.

Audio, Video, and Animations

• Aspect ratio: 16:9 or 4:3
• Maximum file size: 25 GB for high resolution files; 5 GB for low resolution files
• Minimum video duration: 1 sec
• Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

• Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
• A collection of figures may also be combined in a PDF file.

Spreadsheets

• Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

• Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

• It is possible to collect multiple files in a .zip or .gz file.
• If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
• Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
• Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.
• For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

• Supplementary Information (SI) will be published as received from the author without any conversion, editing, or reformatting.

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

• The manuscript contains a descriptive caption for each supplementary material
• Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

This journal follows Springer Nature research data policy . Sharing of all relevant research data is strongly encouraged and authors must add a Data Availability Statement to original research articles.

Research data includes a wide range of types, including spreadsheets, images, textual extracts, archival documents, video or audio, interview notes or any specialist formats generated during research.

Data availability statements

All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here .

If it is not possible to share research data publicly, for instance when individual privacy could be compromised, this statement should describe how data can be accessed and any conditions for reuse. Participant consent should be obtained and documented prior to data collection. See our guidance on sensitive data for more information.

When creating a data availability statement, authors are encouraged to consider the minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article.

Further guidance on writing a data availability statement, including examples, is available at:

Data repositories

Authors are strongly encouraged to deposit their supporting data in a publicly available repository. Sharing your data in a repository promotes the integrity, discovery and reuse of your research, making it easier for the research community to build on and credit your work.

See our data repository guidance for information on finding a suitable repository.

We recommend the use of discipline-specific repositories where available. For a number of data types, submission to specific public repositories is mandatory.

See our list of mandated data types .

The journal encourages making research data available under open licences that permit reuse. The journal does not enforce use of particular licences in third party repositories. You should ensure you have necessary rights to share any data that you deposit in a repository.

Data citation

The journal recommends that authors cite any publicly available data on which the conclusions of the paper rely. This includes data the authors are sharing alongside their publication and any secondary data the authors have reused. Data citations should include a persistent identifier (such as a DOI), should be included in the reference list using the minimum information recommended by DataCite (Dataset Creator, Dataset Title, Publisher [repository], Publication Year, Identifier [e.g. DOI, Handle, Accession or ARK]) and follow journal style.

See our further guidance on citing datasets.

Research data and peer review

If the journal that you are submitting to uses double-anonymous peer review and you are providing reviewers with access to your data (for example via a repository link, supplementary information or data on request), it is strongly suggested that the authorship in the data is also anonymised. There are data repositories that can assist with this and/or will create a link to mask the authorship of your data.

Support with research data policy

Authors who need help understanding our data sharing policy, finding a suitable data repository, or organising and sharing research data can consult our Research Data Helpdesk for guidance.

See our FAQ page for more information on Springer Nature's research data policy.

Upon acceptance, your article will be exported to Production to undergo typesetting. Shortly after this you will receive two e-mails. One contains a request to confirm your affiliation, choose the publishing model for your article, as well as to arrange rights and payment of any associated publication cost. A second e-mail containing a link to your article’s proofs will be sent once typesetting is completed.

Offprints can be ordered by the corresponding author.

Color illustrations

Publication of color illustrations is free of charge.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.

Article processing charges (APCs) vary by journal – view the full list

• Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.

It is easy to find funding to support open access – please see our funding and support pages for more information.

*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Funding and Support pages

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Find more about the license agreement

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics ( COPE ) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.

Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation is helped by following the rules of good scientific practice, which include*:

• The manuscript should not be submitted to more than one journal for simultaneous consideration.
• The submitted work should be original and should not have been published elsewhere in any form or language (partially or in full), unless the new work concerns an expansion of previous work. (Please provide transparency on the re-use of material to avoid the concerns about text-recycling (‘self-plagiarism’).
• A single study should not be split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (i.e. ‘salami-slicing/publishing’).
• Concurrent or secondary publication is sometimes justifiable, provided certain conditions are met. Examples include: translations or a manuscript that is intended for a different group of readers.
• Results should be presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation (including image based manipulation). Authors should adhere to discipline-specific rules for acquiring, selecting and processing data.
• No data, text, or theories by others are presented as if they were the author’s own (‘plagiarism’). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks (to indicate words taken from another source) are used for verbatim copying of material, and permissions secured for material that is copyrighted.

Important note: the journal may use software to screen for plagiarism.

• Authors should make sure they have permissions for the use of software, questionnaires/(web) surveys and scales in their studies (if appropriate).
• Research articles and non-research articles (e.g. Opinion, Review, and Commentary articles) must cite appropriate and relevant literature in support of the claims made. Excessive and inappropriate self-citation or coordinated efforts among several authors to collectively self-cite is strongly discouraged.
• Authors should avoid untrue statements about an entity (who can be an individual person or a company) or descriptions of their behavior or actions that could potentially be seen as personal attacks or allegations about that person.
• Research that may be misapplied to pose a threat to public health or national security should be clearly identified in the manuscript (e.g. dual use of research). Examples include creation of harmful consequences of biological agents or toxins, disruption of immunity of vaccines, unusual hazards in the use of chemicals, weaponization of research/technology (amongst others).
• Authors are strongly advised to ensure the author group, the Corresponding Author, and the order of authors are all correct at submission. Adding and/or deleting authors during the revision stages is generally not permitted, but in some cases may be warranted. Reasons for changes in authorship should be explained in detail. Please note that changes to authorship cannot be made after acceptance of a manuscript.

*All of the above are guidelines and authors need to make sure to respect third parties rights such as copyright and/or moral rights.

Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results presented. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded.

If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher will carry out an investigation following COPE guidelines. If, after investigation, there are valid concerns, the author(s) concerned will be contacted under their given e-mail address and given an opportunity to address the issue. Depending on the situation, this may result in the Journal’s and/or Publisher’s implementation of the following measures, including, but not limited to:

• If the manuscript is still under consideration, it may be rejected and returned to the author.

- an erratum/correction may be placed with the article

- an expression of concern may be placed with the article

- or in severe cases retraction of the article may occur.

The reason will be given in the published erratum/correction, expression of concern or retraction note. Please note that retraction means that the article is maintained on the platform , watermarked “retracted” and the explanation for the retraction is provided in a note linked to the watermarked article.

• The author’s institution may be informed
• A notice of suspected transgression of ethical standards in the peer review system may be included as part of the author’s and article’s bibliographic record.

Fundamental errors

Authors have an obligation to correct mistakes once they discover a significant error or inaccuracy in their published article. The author(s) is/are requested to contact the journal and explain in what sense the error is impacting the article. A decision on how to correct the literature will depend on the nature of the error. This may be a correction or retraction. The retraction note should provide transparency which parts of the article are impacted by the error.

Suggesting / excluding reviewers

Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts. When suggesting reviewers, authors should make sure they are totally independent and not connected to the work in any way. It is strongly recommended to suggest a mix of reviewers from different countries and different institutions. When suggesting reviewers, the Corresponding Author must provide an institutional email address for each suggested reviewer, or, if this is not possible to include other means of verifying the identity such as a link to a personal homepage, a link to the publication record or a researcher or author ID in the submission letter. Please note that the Journal may not use the suggestions, but suggestions are appreciated and may help facilitate the peer review process.

These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines*:

All authors whose names appear on the submission

1) made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work;

2) drafted the work or revised it critically for important intellectual content;

3) approved the version to be published; and

4) agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

* Based on/adapted from:

ICMJE, Defining the Role of Authors and Contributors,

Transparency in authors’ contributions and responsibilities to promote integrity in scientific publication, McNutt at all, PNAS February 27, 2018

Disclosures and declarations

All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate).

The decision whether such information should be included is not only dependent on the scope of the journal, but also the scope of the article. Work submitted for publication may have implications for public health or general welfare and in those cases it is the responsibility of all authors to include the appropriate disclosures and declarations.

Data transparency

All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards. Please note that journals may have individual policies on (sharing) research data in concordance with disciplinary norms and expectations.

Role of the Corresponding Author

One author is assigned as Corresponding Author and acts on behalf of all co-authors and ensures that questions related to the accuracy or integrity of any part of the work are appropriately addressed.

The Corresponding Author is responsible for the following requirements:

• ensuring that all listed authors have approved the manuscript before submission, including the names and order of authors;
• managing all communication between the Journal and all co-authors, before and after publication;*
• providing transparency on re-use of material and mention any unpublished material (for example manuscripts in press) included in the manuscript in a cover letter to the Editor;
• making sure disclosures, declarations and transparency on data statements from all authors are included in the manuscript as appropriate (see above).

* The requirement of managing all communication between the journal and all co-authors during submission and proofing may be delegated to a Contact or Submitting Author. In this case please make sure the Corresponding Author is clearly indicated in the manuscript.

Author contributions

In absence of specific instructions and in research fields where it is possible to describe discrete efforts, the Publisher recommends authors to include contribution statements in the work that specifies the contribution of every author in order to promote transparency. These contributions should be listed at the separate title page.

Examples of such statement(s) are shown below:

• Free text:

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by [full name], [full name] and [full name]. The first draft of the manuscript was written by [full name] and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Example: CRediT taxonomy:

• Conceptualization: [full name], …; Methodology: [full name], …; Formal analysis and investigation: [full name], …; Writing - original draft preparation: [full name, …]; Writing - review and editing: [full name], …; Funding acquisition: [full name], …; Resources: [full name], …; Supervision: [full name],….

For review articles where discrete statements are less applicable a statement should be included who had the idea for the article, who performed the literature search and data analysis, and who drafted and/or critically revised the work.

For articles that are based primarily on the student’s dissertation or thesis , it is recommended that the student is usually listed as principal author:

A Graduate Student’s Guide to Determining Authorship Credit and Authorship Order, APA Science Student Council 2006

Affiliation

The primary affiliation for each author should be the institution where the majority of their work was done. If an author has subsequently moved, the current address may additionally be stated. Addresses will not be updated or changed after publication of the article.

Changes to authorship

Authors are strongly advised to ensure the correct author group, the Corresponding Author, and the order of authors at submission. Changes of authorship by adding or deleting authors, and/or changes in Corresponding Author, and/or changes in the sequence of authors are not accepted after acceptance of a manuscript.

• Please note that author names will be published exactly as they appear on the accepted submission!

Please make sure that the names of all authors are present and correctly spelled, and that addresses and affiliations are current.

Adding and/or deleting authors at revision stage are generally not permitted, but in some cases it may be warranted. Reasons for these changes in authorship should be explained. Approval of the change during revision is at the discretion of the Editor-in-Chief. Please note that journals may have individual policies on adding and/or deleting authors during revision stage.

Author identification

Authors are recommended to use their ORCID ID when submitting an article for consideration or acquire an ORCID ID via the submission process.

Deceased or incapacitated authors

For cases in which a co-author dies or is incapacitated during the writing, submission, or peer-review process, and the co-authors feel it is appropriate to include the author, co-authors should obtain approval from a (legal) representative which could be a direct relative.

Authorship issues or disputes

In the case of an authorship dispute during peer review or after acceptance and publication, the Journal will not be in a position to investigate or adjudicate. Authors will be asked to resolve the dispute themselves. If they are unable the Journal reserves the right to withdraw a manuscript from the editorial process or in case of a published paper raise the issue with the authors’ institution(s) and abide by its guidelines.

Confidentiality

Authors should treat all communication with the Journal as confidential which includes correspondence with direct representatives from the Journal such as Editors-in-Chief and/or Handling Editors and reviewers’ reports unless explicit consent has been received to share information.

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” when submitting a paper:

• Research involving Human Participants and/or Animals

Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. single or double blind peer review) as well as per journal subject discipline. Before submitting your article check the instructions following this section carefully.

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.

The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:

• Research grants from funding agencies (please give the research funder and the grant number)
• Honoraria for speaking at symposia
• Financial support for attending symposia
• Financial support for educational programs
• Employment or consultation
• Support from a project sponsor
• Position on advisory board or board of directors or other type of management relationships
• Multiple affiliations
• Financial relationships, for example equity ownership or investment interest
• Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
• Holdings of spouse and/or children that may have financial interest in the work

In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.

The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms can be found

The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).

Please make sure to submit all Conflict of Interest disclosure forms together with the manuscript.

See below examples of disclosures:

Funding: This study was funded by X (grant number X).

Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

If no conflict exists, the authors should state:

Conflict of Interest: The authors declare that they have no conflict of interest.

When reporting a study that involved human participants, their data or biological material, authors should include a statement that confirms that the study was approved (or granted exemption) by the appropriate institutional and/or national research ethics committee (including the name of the ethics committee) and certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that an independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study. If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the reasons for the exemption).

Retrospective ethics approval

If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the manuscript for peer review. The decision on whether to proceed to peer review in such cases is at the Editor's discretion.

Ethics approval for retrospective studies

Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain) ethics approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.

Ethics approval for case studies

Case reports require ethics approval. Most institutions will have specific policies on this subject. Authors should check with their institution to make sure they are complying with the specific requirements of their institution and seek ethics approval where needed. Authors should be aware to secure informed consent from the individual (or parent or guardian if the participant is a minor or incapable) See also section on Informed Consent .

If human cells are used, authors must declare in the manuscript: what cell lines were used by describing the source of the cell line, including when and from where it was obtained, whether the cell line has recently been authenticated and by what method. If cells were bought from a life science company the following need to be given in the manuscript: name of company (that provided the cells), cell type, number of cell line, and batch of cells.

It is recommended that authors check the NCBI database for misidentification and contamination of human cell lines. This step will alert authors to possible problems with the cell line and may save considerable time and effort.

Further information is available from the International Cell Line Authentication Committee (ICLAC).

Authors should include a statement that confirms that an institutional or independent ethics committee (including the name of the ethics committee) approved the study and that informed consent was obtained from the donor or next of kin.

Research Resource Identifiers (RRID)

Research Resource Identifiers (RRID) are persistent unique identifiers (effectively similar to a DOI) for research resources. This journal encourages authors to adopt RRIDs when reporting key biological resources (antibodies, cell lines, model organisms and tools) in their manuscripts.

Organism: Filip1 tm1a(KOMP)Wtsi RRID:MMRRC_055641-UCD

Cell Line: RST307 cell line RRID:CVCL_C321

Antibody: Luciferase antibody DSHB Cat# LUC-3, RRID:AB_2722109

Plasmid: mRuby3 plasmid RRID:Addgene_104005

Software: ImageJ Version 1.2.4 RRID:SCR_003070

RRIDs are provided by the Resource Identification Portal . Many commonly used research resources already have designated RRIDs. The portal also provides authors links so that they can quickly register a new resource and obtain an RRID.

Clinical Trial Registration

The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to assess, improve, maintain, promote or modify health, functioning or health conditions” and a health-related outcome is generally defined as a change in the health of a person or population as a result of an intervention.

To ensure the integrity of the reporting of patient-centered trials, authors must register prospective clinical trials (phase II to IV trials) in suitable publicly available repositories. For example www.clinicaltrials.gov or any of the primary registries that participate in the WHO International Clinical Trials Registry Platform .

The trial registration number (TRN) and date of registration should be included as the last line of the manuscript abstract.

For clinical trials that have not been registered prospectively, authors are encouraged to register retrospectively to ensure the complete publication of all results. The trial registration number (TRN), date of registration and the words 'retrospectively registered’ should be included as the last line of the manuscript abstract.

Standards of reporting

Springer Nature advocates complete and transparent reporting of biomedical and biological research and research with biological applications. Authors are recommended to adhere to the minimum reporting guidelines hosted by the EQUATOR Network when preparing their manuscript.

Exact requirements may vary depending on the journal; please refer to the journal’s Instructions for Authors.

Checklists are available for a number of study designs, including:

Randomised trials (CONSORT) and Study protocols (SPIRIT)

Observational studies (STROBE)

Systematic reviews and meta-analyses (PRISMA) and protocols (Prisma-P)

Diagnostic/prognostic studies (STARD) and (TRIPOD)

Case reports (CARE)

Clinical practice guidelines (AGREE) and (RIGHT)

Qualitative research (SRQR) and (COREQ)

Animal pre-clinical studies (ARRIVE)

Quality improvement studies (SQUIRE)

Economic evaluations (CHEERS)

Summary of requirements

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Ethics approval’.

Examples of statements to be used when ethics approval has been obtained:

• All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of A (No. ...).

• This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University B (Date.../No. ...).

• Approval was obtained from the ethics committee of University C. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

• The questionnaire and methodology for this study was approved by the Human Research Ethics committee of the University of D (Ethics approval number: ...).

Examples of statements to be used for a retrospective study:

• Ethical approval was waived by the local Ethics Committee of University A in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.

• This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of XYZ who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB of XYZ.

• This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University B approved this study.

Examples of statements to be used when no ethical approval is required/exemption granted:

• This is an observational study. The XYZ Research Ethics Committee has confirmed that no ethical approval is required.

• The data reproduced from Article X utilized human tissue that was procured via our Biobank AB, which provides de-identified samples. This study was reviewed and deemed exempt by our XYZ Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Authors are responsible for correctness of the statements provided in the manuscript. See also Authorship Principles. The Editor-in-Chief reserves the right to reject submissions that do not meet the guidelines described in this section.

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. This is especially true concerning images of vulnerable people (e.g. minors, patients, refugees, etc) or the use of images in sensitive contexts. In many instances authors will need to secure written consent before including images.

Identifying details (names, dates of birth, identity numbers, biometrical characteristics (such as facial features, fingerprint, writing style, voice pattern, DNA or other distinguishing characteristic) and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scholarly purposes and the participant (or parent/guardian if the participant is a minor or incapable or legal representative) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases. Detailed descriptions of individual participants, whether of their whole bodies or of body sections, may lead to disclosure of their identity. Under certain circumstances consent is not required as long as information is anonymized and the submission does not include images that may identify the person.

Informed consent for publication should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort meaning.

Exceptions where it is not necessary to obtain consent:

• Images such as x rays, laparoscopic images, ultrasound images, brain scans, pathology slides unless there is a concern about identifying information in which case, authors should ensure that consent is obtained.

• Reuse of images: If images are being reused from prior publications, the Publisher will assume that the prior publication obtained the relevant information regarding consent. Authors should provide the appropriate attribution for republished images.

Consent and already available data and/or biologic material

Regardless of whether material is collected from living or dead patients, they (family or guardian if the deceased has not made a pre-mortem decision) must have given prior written consent. The aspect of confidentiality as well as any wishes from the deceased should be respected.

Data protection, confidentiality and privacy

When biological material is donated for or data is generated as part of a research project authors should ensure, as part of the informed consent procedure, that the participants are made aware what kind of (personal) data will be processed, how it will be used and for what purpose. In case of data acquired via a biobank/biorepository, it is possible they apply a broad consent which allows research participants to consent to a broad range of uses of their data and samples which is regarded by research ethics committees as specific enough to be considered “informed”. However, authors should always check the specific biobank/biorepository policies or any other type of data provider policies (in case of non-bio research) to be sure that this is the case.

Consent to Participate

For all research involving human subjects, freely-given, informed consent to participate in the study must be obtained from participants (or their parent or legal guardian in the case of children under 16) and a statement to this effect should appear in the manuscript. In the case of articles describing human transplantation studies, authors must include a statement declaring that no organs/tissues were obtained from prisoners and must also name the institution(s)/clinic(s)/department(s) via which organs/tissues were obtained. For manuscripts reporting studies involving vulnerable groups where there is the potential for coercion or where consent may not have been fully informed, extra care will be taken by the editor and may be referred to the Springer Nature Research Integrity Group.

Consent to Publish

Individuals may consent to participate in a study, but object to having their data published in a journal article. Authors should make sure to also seek consent from individuals to publish their data prior to submitting their paper to a journal. This is in particular applicable to case studies. A consent to publish form can be found

here. (Download docx, 36 kB)

The above should be summarized in a statement and placed in a ‘Declarations’ section before the reference list under a heading of ‘Consent to participate’ and/or ‘Consent to publish’. Other declarations include Funding, Competing interests, Ethics approval, Consent, Data and/or Code availability and Authors’ contribution statements.

Please see the various examples of wording below and revise/customize the sample statements according to your own needs.

Sample statements for "Consent to participate" :

Informed consent was obtained from all individual participants included in the study.

Informed consent was obtained from legal guardians.

Written informed consent was obtained from the parents.

Verbal informed consent was obtained prior to the interview.

Sample statements for “Consent to publish” :

The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1a, 1b and 1c.

The participant has consented to the submission of the case report to the journal.

Patients signed informed consent regarding publishing their data and photographs.

Sample statements if identifying information about participants is available in the article:

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Images will be removed from publication if authors have not obtained informed consent or the paper may be removed and replaced with a notice explaining the reason for removal.

How can you help improve your manuscript for publication?

Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. The experts at Springer Nature Author Services can help you with manuscript preparation—including English language editing, developmental comments, manuscript formatting, figure preparation, translation , and more.

Get started and save 15%

You can also use our free Grammar Check tool for an evaluation of your work.

Please note that using these tools, or any other service, is not a requirement for publication, nor does it imply or guarantee that editors will accept the article, or even select it for peer review.

Chinese (中文)

您怎么做才有助于改进您的稿件以便顺利发表？

如果在结构精巧的稿件中用精心组织的英语展示您的作品，就能最大限度地让编辑和审稿人理解并公正评估您的作品。许多研究人员发现，获得一些独立支持有助于他们以尽可能美好的方式展示他们的成果。Springer Nature Author Services 的专家可帮助您准备稿件，具体包括 润色英语表述、添加有见地的注释、为稿件排版、设计图表、翻译 等。

开始使用即可节省 15% 的费用

您还可以使用我们的 免费语法检查工具 来评估您的作品。

请注意，使用这些工具或任何其他服务不是发表前必须满足的要求，也不暗示或保证相关文章定会被编辑接受（甚至未必会被选送同行评审）。

Japanese (日本語)

発表に備えて、論文を改善するにはどうすればよいでしょうか？

内容が適切に組み立てられ、質の高い英語で書かれた論文を投稿すれば、編集者や査読者が論文を理解し、公正に評価するための最善の機会となります。多くの研究者は、個別のサポートを受けることで、研究結果を可能な限り最高の形で発表できると思っています。Springer Nature Author Servicesのエキスパートが、 英文の編集、建設的な提言、論文の書式、図の調整、翻訳 など、論文の作成をサポートいたします。

今なら15％割引でご利用いただけます

原稿の評価に、無料 の文法チェック ツールもご利用いただけます。

これらのツールや他のサービスをご利用いただくことは、論文を掲載するための要件ではありません。また、編集者が論文を受理したり、査読に選定したりすることを示唆または保証するものではないことにご注意ください。

Korean (한국어)

게재를 위해 원고를 개선하려면 어떻게 해야 할까요?

여러분의 작품을 체계적인 원고로 발표하는 것은 편집자와 심사자가 여러분의 연구를 이해하고 공정하게 평가할 수 있는 최선의 기회를 제공합니다. 많은 연구자들은 어느 정도 독립적인 지원을 받는 것이 가능한 한 최선의 방법으로 자신의 결과를 발표하는 데 도움이 된다고 합니다. Springer Nature Author Services 전문가들은 영어 편집, 발전적인 논평, 원고 서식 지정, 그림 준비, 번역 등과 같은 원고 준비를 도와드릴 수 있습니다.

지금 시작하면 15% 할인됩니다.

또한 당사의 무료 문법 검사 도구를 사용하여 여러분의 연구를 평가할 수 있습니다.

이러한 도구 또는 기타 서비스를 사용하는 것은 게재를 위한 필수 요구사항이 아니며, 편집자가 해당 논문을 수락하거나 피어 리뷰에 해당 논문을 선택한다는 것을 암시하거나 보장하지는 않습니다.

To find out more about publishing your work Open Access in Breast Cancer Research and Treatment , including information on fees, funding and licences, visit our Open access publishing page .

• Find a journal
• Publish with us
• Track your research

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

About the Editors

Editor-in-chief.

Dr. Larry Norton is a board-certified medical oncologist with broad interests in cancer prevention, diagnosis and treatment. His research concerns the basic biology of cancer, the mathematics of tumor causation and growth and the development of approaches to better diagnosis, prevention and drug treatment of the disease. He is involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors and vaccines. A major milestone in his research career was the development of an approach to therapy called "dose density," or "sequential dose density."

Deputy Editors

Sunil Badve, M.D., FRCPath, is the Vice Chair, and Director of the Pathology Cancer Program at Emory University. He is a surgical pathologist and a translational researcher in breast cancer for over 20 years. Dr. Badve has been recognized by the Scholar Award from Susan G. Komen for the Cure (2010-2018 and Current 2022-2025) as Best Doctor and has received the AACR Team Sciences Award (2020) as a member of the TCGA Team. Dr. Badve has served on several committees including – the (NCI) Breast Oncology Local Disease, the ECOG Breast Committees, the AJCC (8th edition) and WHO for breast and thymic cancers. Dr. Badve currently serves on the NCI Breast Cancer Steering Committee, and have served on the Breast Cancer Correlative Sciences Committee, and the ASCO-CAP committee to develop guidelines for hormone receptor testing.  

Zoltan Szallasi, MD is a senior research scientist in the Computational Health Informatics Program, at Children’s Hospital, Boston, Harvard Medical School. Dr. Szallasi's group has been applying genomics to characterize key cancer associated biological processes. His main work is focusing around detecting and quantifying DNA repair deficiencies in breast cancer and other solid tumors using next generation sequencing data. The main goal of this work is to enable synthetic lethality driven cancer therapies that target aberrations in specific DNA repair pathways such as homologous recombination or nucleotide excision repair.

Dr. Sarat Chandarlapaty is a Member and Laboratory Head in the Human Oncology and Pathogenesis Program and the Breast Cancer Medicine Service at Memorial Sloan Kettering. The goal of Dr. Chandarlapaty’s research is to investigate the mechanisms and consequences of activation of growth factor and hormonal signaling pathways in breast cancer and translate those findings towards the development of more effective and durable treatments for metastatic disease. A major focus of his laboratory has been to characterize the significance of alterations present in breast tumors that have progressed on targeted therapy and devise therapeutic strategies that can overcome these forms of drug resistance.

Managing Editor

Aparna anantharaman, phd .

Aparna earned her PhD in bioscience from New Delhi, India where she designed and tested antibiotic peptides against pathogenic bacteria. She then moved to the US to work as a postdoctoral researcher and gained over nine years of research experience in gene regulation and RNA biology. Aparna has expertise in advanced molecular and cellular biology, biochemistry, biophysics, and basic bioinformatics. She transitioned into publishing in 2023 and now serves as a Managing Editor for the npj Series. She is based in the Philadelphia office.

Associate Editors

Caterina Marchiò leads the Research Program of the Pathology Unit at the Candiolo Cancer Institute where her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive and HER2-low carcinomas. She is actively involved in the standardization of preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens to guarantee the success of precision medicine.

Andrea Richardson M.D. Ph.D. is Associate Professor and Director of Pathology for the Johns Hopkins Medicine National Capital Region where she is a practicing physician and translational breast cancer scientist. Her research has focused on characterizing the molecular aberrations in subtypes of breast cancer important for pathogenesis, tumor progression, and tumor response to therapy. Through genomic analysis of tissues, her laboratory identified a DNA damage signature termed NtAI that is high in BRCA-like cancers and predicts for response to certain drugs. Myriad has developed this predictor into a commercial test (MyChoice CDx) which is now available for clinical use. Her current research expands on these findings to study the role of mutational signatures in tumors and cell line models to predict for DNA damage repair defects and drug sensitivity.

Professor of Pathology at the University of Porto, Director of RISE (Clinical and Translational Research Network of the Medical Faculty) and Head of Molecular Pathology at IPATIMUP.Past-President of the International Society of Breast Pathology and General Secretary and President-elect of the International Academy of Cytology (IAC). He has authored more than 500 papers in peer-review journals, 33 book chapters and he is editor of 6 books. He is widely considered a world-leading expert in cytopathology and breast cancer. His research work is on breast cancer, with emphasis on molecular markers and therapeutic targets.

Founding Editor

Cliff Hudis is a medical oncologist with research interests in all areas of care related to breast cancer. A particular research focus of his team is the interplay between inflammation, obesity and breast cancer, and they are now actively translating their findings into clinically relevant trials with the potential to reduce the global burden of breast and other cancers.

Advisory Editor

Editorial Board Members 

Kathy S. Albain, MD, FACP Loyola University Chicago, IL, USA Sunil Badve, MD  Indiana University School of Medicine, Indiana, USA Gabor Balázsi, PhD Stony Brook University, New York, USA John M.S. Bartlett, PhD Ontario Institute for Cancer Research Toronto, Ontario, Canada Debra L. Barton, PhD University of Michigan, MI, USA Powel H. Brown, MD University of Texas, MD Anderson Cancer Center Houston, Texas, USA Maggie Cheang, MD The Institute of Cancer Research Surrey, London, UK Lewis A. Chodosh, MD University of Pennsylvania, Pennsylvania, USA Carsten Denkert, MD, PhD Charité Universitätsmedizin Berlin, Berlin, Germany Matthew J. Ellis,   BSc, MB, BChir, PhD, FRCP  Baylor College of Medicine, Texas, USA Prudence A. Francis, MD  Peter MacCallum Cancer Centre, Melbourne, Australia Benita S. Katzenellenbogen, MD University of Illinois Urbana-Champaign, Illinois, USA Seema A. Khan, MD Northwestern University Evanston, Illinois, USA Ian E. Krop, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School, MA, USA Adrian V. Lee, PhD University of Pittsburgh, Pennsylvania, USA Ephrat Levy-Lahad, MD Shaare Zedek Medical Center, Jerusalem, Israel Sherene Loi, MD, PhD University of Melbourne, Melbourne, Australia Caterina Marchio, PhD University of Turin, Turin, Italy Stefan Michiels, PhD Université Paris-Sud Paris, Paris, France Harikrishna Nakshatri, PhD,  Indiana University School of Medicine, USA Kenneth Offit, MD, MPH Memorial Sloan Kettering Cancer Center, New York, USA Edith A. Perez, MD Mayo Clinic Jacksonville, Florida, USA Stuart J. Schnitt, MD Brigham and Women's Hospital, Massachusetts, USA Dipali Sharma, PhD Professor of Oncology, Johns Hopkins, USA Valerie Speirs, PhD Leeds Institute of Cancer & Pathology, Leeds, United Kingdom Anne Vincent-Salomon, PhD  Institut Curie Paris, Paris, France Geoffrey M. Wahl, MD Salk Institute La Jolla, California, USA Jedd Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center, New York, USA

Interested in joining the journal team?

If you are interested in joining the journal as an Editorial Board Member or Associate Editor, please complete this Google form . Associate Editors are part of the editorial team that handle manuscripts, while Editorial Board Members are regular reviewers and are consulted for ad hoc advice. We will contact you if your expertise meets the needs of the journal.

Nature Portfolio journals are committed to promoting practices that support diversity, equity and inclusion in science communication and publishing, and we strongly encourage gender, race, ethnic, geographic, career stage and other diversity in our journal teams. Our in-house staff will use your information only for the purposes of identifying new editorial team or board members. Please contact the journal by email if you would like to remove your information from these records.

Please note that we are not able to respond to all applicants.

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

2024 January 18 Purpose This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Materials and Methods In this open-label, singl... ORIGINAL ARTICLE 2024 January 8 Purpose There have been needs to improve the sensitivity of liquid biopsy. This report aims to report the analytical and clinical validation of a next-generation sequencing (NGS)–based circulating tumor DNA (ctDNA) assay. Materials and Methods Analytical validation was conduct... ORIGINAL ARTICLE 2024 January 30 and Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience Purpose Exon 20 insertion mutations (E20ins) in epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) in non–small cell lung cancer (NSCLC) patients has become more important with emergence of novel agents targeting E20ins. Materials and Me... Accepted and E-pub version articles are published online before they appear in a regular issue of the journal. Accepted articles are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. The accepted article remains on this page until the final proof version of the paper is posted in Epub Ahead-of Print page. Accepted article is given its own Doi, so it can be citable as it has been linked to PubMed. It may be cited as shown in the following example: Original Articles     --> --> Korean Cancer Association Room 1824, Gwanghwamun Officia 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail:  |   |   |  An official website of the United States government The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Publications Account settings Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now . Advanced Search Journal List Front Mol Biosci Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers Nicola fusco. 1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy 2 Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy Umberto Malapelle 3 Department of Public Health, Federico II University of Naples, Naples, Italy Carmen Criscitiello 4 Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology, Milan, Italy We are experiencing an amazing era of advances in the diagnosis and treatment of breast cancer, with the discovery of novel actionable biomarkers (e.g., programmed death-ligand 1 (PD-L1), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha ( PIK3CA ), mismatch repair) and the re-discovery of traditional and established ones, particularly for HER2 (low expression/mutations) ( Tarantino et al., 2020 ; Fusco et al., 2021a ; Sajjadi et al., 2021 ; Criscitiello et al., 2022 ). These biomarkers are strongly impacting pathology and treatment decision-making in oncology, with the introduction of ultra-personalized therapeutic options ( Punturi et al., 2021 ; Venetis et al., 2022a ; Henry et al., 2022 ; Tarantino et al., 2022 ). In this evolving scenario, predictive molecular pathology is called to face new challenges in breast cancer ( Fusco et al., 2021b ; Dileep and Gianchandani Gyani, 2022 ). Our improved diagnostic resolution, together with the combination of clinicopathologic data and massive molecular and digital data, is allowing targeted therapies to become more and more selective ( Pisapia et al., 2022 ). The multi-dimension of this approach requires extremely precise testing methods and guidelines. We edited the present Research Topic of Frontiers in Molecular Biosciences on The Rise of Novel Molecular Biomarkers in Breast cancer (2022 edition) to provide a snapshot of novel significant advances in the evolving field of breast cancer biomarkers. We selected two original research articles and two comprehensive reviews covering different aspects of biomarkers in breast cancer. Among these, an original research article by Elham Sajjadi and collaborators provides previously unavailable evidence on the biology underpinning invasive breast carcinomas with osteoclast-like stromal giant cells (OSGC) ( Sajjadi et al., 2022 ). Through a comprehensive characterization of the different cellular compartments of this exceedingly rare type of tumor, the Authors investigated the similarities of OSGC with tumor and tumor immune microenvironment in terms of morphology, protein, and monocytic miRNA signatures. This comprehensive approach unveiled shared epigenetic events during the ontogenesis of breast cancer cells and OSGC, with the latter belonging to the spectrum of M2 tumor-associated macrophages. Another mRNA study by Chen et al . Depicts the prognostic value and biological role of protein tyrosine kinase 2 (PTK2) in breast cancer Chen et al. This elegant work has been particularly welcomed by the Editorial Board, given the integration of multiple publicly available databases. The Authors found that PTK2 mRNA is upregulated in breast cancer cells compared to the normal breast tissue and that it may give significant prognostic information, being associated with high-stage, mutations in well-known cancer genes, and poor survival. Quality of life Research Topic is a crucial burden in breast cancer survivors and there is accumulating evidence on the role of biomarkers in this spectrum of conditions ( Maurer et al., 2021 ; Sunilkumar et al., 2021 ; Invernizzi et al. ). In this respect, a multicentric Italian effort led by Prof. Marco Invernizzi clarifies the current state of knowledge on biomarkers that might be potentially integrated into rehabilitation practice to promote a precision medicine approach to breast cancer-specific survivorship Research Topic Invernizzi et al. This systematic review, which includes 22 randomized controlled trials assessing rehabilitation interventions in patients with breast cancer, reveals that physical exercise in patients with a diagnosis of breast cancer induce the presence of recurrent molecular alterations in key molecules, thus corroborating the need for translational research focused on the role of biomarkers in tailored rehabilitative treatments in these women. Finally, we are delighted to offer to the readership of this Research Topic some real-world data by Di Cosimo S. et al. On the prevalence, treatment response, and outcome of patients with HER2-low breast cancer Di Cosimo et al. This study is of particular relevance given that the introduction of novel anti-HER2 compounds is determining a paradigm shift in breast cancer treatment, as tumors with low levels of HER2 expression (i.e., score 1+/2+ with no gene amplification) benefit from HER2 antibody-drug conjugates (ADC) ( Venetis et al., 2022b ). In this article, patients with HER2-low breast cancer account for ∼50% of the cases treated with neoadjuvant therapy and have poor treatment responses. In the absence of pathologic complete response (pCR), these patients, particularly those with a triple-negative neoplasm, have a dismal prognosis. Studies are needed not only to better define the biology of HER2-low breast cancer but also to investigate the possible role of new therapeutic approaches in the early stage. Our understanding of the molecular landscape of breast cancer is expanding day by day. We believe that a biomarker-based approach being able to identify specific subgroups of patients is now mandatory in breast cancer precision oncology. Hence, precision medicine should ideally start in the pathology lab and expand to the clinic, keeping the patients at the center of their management. Acknowledgments This Research Topic was developed in collaboration with 4oncommunity breast ( www.4oncommunity.com Twitter: @4oncommunity), a virtual space to share experiences and knowledge for the advancement of the breast cancer professionals community. Author contributions All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Conflict of interest NF has received honoraria for consulting, advisory role, speaker bureau, travel, and/or research grants from Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Novartis, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline (GSK), Gilead, Diaceutics, Adicet Bio, and Sermonix. UM has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis, and Hedera. CC reports personal fees for consulting, advisory role and speakers’ bureau from Roche, Novartis, Pfizer, Lilly, MSD, AstraZeneca, Gilead, Seagen, and Daiichi Sankyo. These companies had no role in the design of the study; in the Research Topic, analyses, or interpretation of data; in the writing of the manuscript, and/or in this editorial activity. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Criscitiello C., Guerini-Rocco E., Viale G., Fumagalli C., Sajjadi E., Venetis K., et al. (2022). Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology . Anticancer Agents Med. Chem. 22 ( 4 ), 787–800. 10.2174/1871520621666210706144112 [ PubMed ] [ CrossRef ] [ Google Scholar ] Dileep G., Gianchandani Gyani S. G. (2022). Artificial intelligence in breast cancer screening and diagnosis . Cureus 14 ( 10 ), e30318. 10.7759/cureus.30318 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Fusco N., Malapelle U., Fassan M., Marchiò C., Buglioni S., Zupo S., et al. (2021). PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer . Front. Oncol. 11 , 644737. 10.3389/fonc.2021.644737 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Fusco N., Ragazzi M., Sajjadi E., Venetis K., Piciotti R., Morganti S., et al. (2021). Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists . Histol. Histopathol. 36 , 1235–1245. 10.14670/hh-18-376 [ PubMed ] [ CrossRef ] [ Google Scholar ] Henry N. L., Somerfield M. R., Dayao Z., Elias A., Kalinsky K., McShane L. M., et al. (2022). Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update . J. Clin. Oncol. 022 ( 0 ), 3205–3221. 10.1200/jco.22.01063 [ PubMed ] [ CrossRef ] [ Google Scholar ] Invernizzi M., de Sire A., Venetis K., Cigna E., Carda S., Borg M., et al. (2022). Quality of life interventions in breast cancer survivors: State of the art in targeted rehabilitation strategies . Anticancer Agents Med. Chem. 22 ( 4 ), 801–810. 10.2174/1871520621666210609095602 [ PubMed ] [ CrossRef ] [ Google Scholar ] Maurer T., Jaskulski S., Behrens S., Jung A. Y., Obi N., Johnson T., et al. (2021). Tired of feeling tired - the role of circulating inflammatory biomarkers and long-term cancer related fatigue in breast cancer survivors . Breastedinbg. Scotl. 56 , 103–109. 10.1016/j.breast.2021.02.008 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Pisapia P., L'Imperio V., Galuppini F., Sajjadi E., Russo A., Cerbelli B., et al. (2022). The evolving landscape of anatomic pathology . Crit. Rev. Oncol. Hematol. 178 , 103776. 10.1016/j.critrevonc.2022.103776 [ PubMed ] [ CrossRef ] [ Google Scholar ] Punturi N. B., Seker S., Devarakonda V., Mazumder A., Kalra R., Chen C. H., et al. (2021). Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer . Nat. Commun. 12 ( 1 ), 2940. 10.1038/s41467-021-23271-0 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Sajjadi E., Venetis K., Piciotti R., Invernizzi M., Guerini-Rocco E., Haricharan S., et al. (2021). Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization . Cancer Cell Int. 21 ( 1 ), 266. 10.1186/s12935-021-01976-y [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Sunilkumar M. M., Finni C. G., Lijimol A. S., Rajagopal M. R. (2021). Health-Related suffering and palliative care in breast cancer . Curr. Breast Cancer Rep. 13 , 241–246. 10.1007/s12609-021-00431-1 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Tarantino P., Hamilton E., Tolaney S. M., Cortes J., Morganti S., Ferraro E., et al. (2020). HER2-Low breast cancer: Pathological and clinical landscape . J. Clin. Oncol. 38 ( 17 ), 1951–1962. 10.1200/jco.19.02488 [ PubMed ] [ CrossRef ] [ Google Scholar ] Tarantino P., Jin Q., Tayob N., Jeselsohn R. M., Schnitt S. J., Vincuilla J., et al. (2022). Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer . JAMA Oncol. 8 , 1177–1183. 10.1001/jamaoncol.2022.2286 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Venetis K., Pepe F., Munzone E., Sajjadi E., Russo G., Pisapia P., et al. (2022). Analytical performance of next-generation sequencing and RT-PCR on formalin-fixed paraffin-embedded tumor tissues for PIK3CA testing in HR+/HER2− breast cancer . Cells 11 ( 22 ), 3545. 10.3390/cells11223545 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Venetis K., Crimini E., Sajjadi E., Corti C., Guerini-Rocco E., Viale G., et al. (2022). HER2 low, ultra-low, and novel complementary biomarkers: Expanding the spectrum of HER2 positivity in breast cancer . Front. Mol. Biosci. 9 , 834651. 10.3389/fmolb.2022.834651 [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ] Breast Cancer Research Breast Cancer Risk Factors Breast Cancer Research  is presenting our Retrospective Collection on "Breast Cancer Risk Factors." Celebrating 'Breast Cancer Awareness Month (1 October- 31 October)', with this Collection, we aim to gain valuable insights into the multifaceted aspects of breast cancer risk to promote awareness, prevention, and early detection. NEW CROSS-JOURNAL COLLECTIONS Find out more by clicking the links below: Artif icial Intelligence in Breast Imaging PDGFB in Br east Cancer Initiation,Progression, and Metastasis Aims and scope Most accessed Elevated expression of Aurora-A/ AURKA in breast cancer associates with younger age and aggressive features Authors: L. M. Ingebriktsen, R. O. C. Humlevik, A. A. Svanøe, A. K. M. Sæle, I. Winge, K. Toska, M. B. Kalvenes, B. Davidsen, A. Heie, G. Knutsvik, C. Askeland, I. M. Stefansson, E. A. Hoivik, L. A. Akslen and E. Wik Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance Authors: Mieke R. Van Bockstal, Jelle Wesseling, Ester H. Lips, Marjolein Smidt, Christine Galant and Carolien H. M. van Deurzen Weakly-supervised deep learning models enable HER2-low prediction from H &E stained slides Authors: Renan Valieris, Luan Martins, Alexandre Defelicibus, Adriana Passos Bueno, Cynthia Aparecida Bueno de Toledo Osorio, Dirce Carraro, Emmanuel Dias-Neto, Rafael A. Rosales, Jose Marcio Barros de Figueiredo and Israel Tojal da Silva Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images Authors: Abhinav Sharma, Sandy Kang Lövgren, Kajsa Ledesma Eriksson, Yinxi Wang, Stephanie Robertson, Johan Hartman and Mattias Rantalainen The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma Authors: Núria Moragas, Patricia Fernandez-Nogueira, Leire Recalde-Percaz, Jamie L. Inman, Anna López-Plana, Helga Bergholtz, Aleix Noguera-Castells, Pedro J. del Burgo, Xieng Chen, Therese Sorlie, Pere Gascón, Paloma Bragado, Mina Bissell, Neus Carbó and Gemma Fuster Most recent articles RSS View all articles Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib Authors: Nusayba Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, Jakob Karen, Magnus Neumüller, Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew Ellis… Choosing the right cell line for breast cancer research Authors: Deborah L Holliday and Valerie Speirs Triple-negative breast cancer molecular subtyping and treatment progress Authors: Li Yin, Jiang-Jie Duan, Xiu-Wu Bian and Shi-cang Yu Breast asymmetry and predisposition to breast cancer Authors: Diane Scutt, Gillian A Lancaster and John T Manning Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer Authors: Suzanne A Eccles, Eric O Aboagye, Simak Ali, Annie S Anderson, Jo Armes, Fedor Berditchevski, Jeremy P Blaydes, Keith Brennan, Nicola J Brown, Helen E Bryant, Nigel J Bundred, Joy M Burchell, Anna M Campbell, Jason S Carroll, Robert B Clarke, Charlotte E Coles… Most accessed articles RSS Editor-in-Chief Lewis Chodosh , University of Pennsylvania, USA Trending in the Media Click  here  to see the most popular articles published in Breast Cancer Research  in the past three months. BCR's 20th Anniversary 20 years ago Breast Cancer Research published its first articles with BMC. Well-respected in the field, the journal has continually placed in the first quartile of the ‘Oncology’ category of Journal Citation Reports. Over the past decade, Breast Cancer Research (BCR) has also become the highest ranked breast cancer focused title in the field. Look back at the journal’s milestone achievements and article highlights . Featured Review - Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review In this review, we provide a useful reference for AI researchers investigating image-based breast cancer risk assessment while indicating key priorities and challenges that, if properly addressed, could accelerate the implementation of AI-assisted risk stratification to future refine and individualize breast cancer screening strategies. Springer Nature Oncology Portfolio Discover the range of academic oncology titles at Springer Nature  here . Interim Editor-In-Chief Jay a. baker, md, facr, fsbi  [email protected] interim editor-in-chief, journal of breast imaging duke university medical center  durham, nc, usa. Jay A. Baker, MD, FACR, FSBI, is a Professor of Radiology at Duke University. He is the Vice-Chair of Faculty Affairs at Duke Radiology and a Past-President of the Society of Breast Imaging. Dr. Baker's research interests include a broad range of issues related to breast imaging including computer-aided diagnosis, evidence-based improvements in the clinical operations of breast imaging, and improving interpretation of traditional mammography, breast tomosynthesis, and breast ultrasound. Associate Editors Wendie berg, md, phd, facr, fsbi  [email protected] associate editor for radiologic-pathologic correlation university of pittsburgh school of medicine pittsburgh, pa, usa. Wendie A. Berg, MD, PhD, FACR, FSBI, is Distinguished Professor of Radiology and the Dr. Bernard F. Fisher Chair of Breast Cancer Clinical Science. at University of Pittsburgh School of Medicine, UPMC Magee-Womens Hospital. Dr. Berg was PI of ACRIN 6666, Screening Breast Ultrasound and MRI in High-Risk Women, and is currently conducting several studies of screening contrast-enhanced mammography. She is interested in use of portable ultrasound and artificial intelligence to improve access in low-resource settings and led analysis of such a study in Mexico. She also led clinical trials of positron emission mammography and MRI for disease extent and led analysis of multicenter results using shear-wave elastography to reduce benign breast biopsies. She helped launch and is Chief Scientific Advisor to DenseBreast-info.org and wrote and co-edited three editions of  Diagnostic Imaging: Breast . Brian N. Dontchos, MD, FSBI [email protected] Associate Editor for Scientific Reviews University of Washington, Fred Hutchison Cancer Center Seattle, WA, USA Brian N. Dontchos, MD, is an Associate Professor of Radiology at the University of Washington (UW) and serves as the Clinical Director of Breast Imaging at Fred Hutchinson Cancer Center. He is also the Director of Patient Access and Clinical Efficiency in the UW Department of Radiology. Prior to his time at the University of Washington, he served as the Service Chief of Breast Imaging at Massachusetts General Hospital (MGH). He graduated cum laude from the University of Pittsburgh School of Medicine in 2008 and was elected to the Alpha Omega Alpha and Gold Humanism Honor Societies during his time in medical school. He then went on to complete his Diagnostic Radiology residency and Breast Imaging fellowship at UW. Dr. Dontchos is passionate about clinical implementation of creative workflows and new technologies with an eye towards improving patient access and clinical efficiency. Specific major clinical initiatives have included clinical implementation of same-day breast biopsy and immediate read screening mammography programs at MGH, with his manuscript on immediate read screening mammography being selected for a Best of AJR 2022 Award . He has also served as a research mentor for numerous Breast Imaging fellows, several winning the Conquer Cancer Foundation Fellow Award by the American Society of Clinical Oncologists for their efforts. Yiming Gao, MD, FSBI  [email protected] Associate Editor for Training and Professional Development New York University Grossman School of Medicine New York, NY, USA Yiming Gao, MD FSBI, is an Associate Professor of Radiology at New York University Grossman School of Medicine, where she serves as Associate Section Chief of the Division of Breast Imaging and was previously the Fellowship Program Director. Dr. Gao received her training in diagnostic radiology in Boston at the Beth Israel Deaconess Medical Center and completed fellowship training at Massachusetts General Hospital. Her research interests focus on advanced imaging techniques and improving breast imaging outcomes. Dr. Gao has an interest in radiology education, currently serving on the SBI CME committee, and having previously done editorial work for the RSNA and the AJR. Samantha L. Heller, MD, PhD, FSBI  [email protected] Associate Editor for Science of Screening New York University Grossman School of Medicine New York, NY, USA Samantha L. Heller, MD, PhD, FSBI, is a Professor of Radiology at New York University Grossman School of Medicine and Section Head of the Division of Breast Imaging. Dr. Heller received her undergraduate degree from Harvard College and her PhD in English literature from Columbia University. She then obtained her medical degree from Weill Cornell Medical School followed by an internship at Memorial Sloan Kettering and a radiology residency and fellowship at NYU.  She subsequently worked in the United Kingdom National Health South West London Breast Cancer Screening Service before joining the faculty of NYU School of Medicine in 2015. She is on the Editorial Board of  RadioGraphics  and was previously on the Editorial Board of the  British Journal of Radiology . She has an interest in screening outcomes and utilization and in improving the specificity of breast imaging. Toma S. Omofoye, MD [email protected] Associate Editor for Image Spotlight and Unknowns The University of Texas MD Anderson Cancer Center Houston, TX, USA Toma S. Omofoye, MD, is an Associate Professor of Radiology and Strategic Director for Education in the Department of Breast Imaging at the University of Texas MD Anderson Cancer, Houston, Texas. She obtained her medical degree and diagnostic radiology training at Duke University. She completed breast imaging fellowship training at MD Anderson Cancer Center. Dr. Omofoye is passionate about global health and radiology education, implementing educational initiatives across multiple continents. She serves as faculty with RSNA’s Global Learning Team in Tanzania, which is tasked with creating the first Women's Imaging fellowship program in sub-Saharan Africa. She is a recipient of the Helen C. Redman, MD, and Marten F. Klop International Education Scholar Grant from the RSNA creating hybrid educational interventions for radiologists and trainees around the world. Stephen J. Seiler, MD, FSBI [email protected] Associate Editor for Clinical Practice University of Texas Southwestern Medical Center Dallas, Texas, USA Stephen J. Seiler, MD, FSBI is Associate Professor of Radiology at the University of Texas Southwestern Medical Center and Chief of the Division of Breast Imaging.  Dr. Seiler graduated with highest honors from the Plan II Honors program at the University of Texas at Austin and obtained his medical degree from UT Southwestern Medical School.  He completed his Diagnostic Radiology residency and breast imaging fellowship at UT Southwestern.  Serving as medical director for the breast imaging clinics within the Harold C. Simmons Comprehensive Cancer Center, he is deeply committed to enhancing clinical operations, achieving workflow efficiencies, and fostering multidisciplinary collaborations.  Dr. Seiler’s research interests include breast implant imaging, breast MRI, and breast ultrasound. Nidhi Sharma, MD Associate Editor for Social Media Texas A&M University Dallas, TX, USA [email protected] Twitter: @sbi_jbi Dr. Sharma is a passionate educator and Associate Professor of Radiology at Texas A&M University. She is the current Editor for Society of Breast Imaging Newsletter. She has held roles of fellowship director and residency liaison for Breast Imaging at Baylor University Medical Center in Dallas, Texas. She attended medical school in India at Armed Forces Medical College and trained and worked at Cleveland Clinic for several years in the role of medical student director. She is the prior Chairperson for the Young Physician Section of Texas Radiological Society, and currently serves as the Councilor for Texas Radiological Society. She is a reviewer for multiple journals including JBI, for which she has received Outstanding reviewer award last three years in a row. She has authored several book chapters, papers and received grants for clinical research.  Lilian C. Wang, MD [email protected] Associate Editor for Education Northwestern University Feinberg School of Medicine Chicago, IL, USA Lilian Wang, MD is an Associate Professor in the Department of Radiology and Breast Imaging Fellowship Program Director at Northwestern University, Feinberg School of Medicine. Dr. Wang received her undergraduate degree in Molecular Biology at Princeton University and her medical degree from Washington University in St. Louis. She then completed residency training at the University of Washington followed by a Breast Imaging fellowship at Northwestern University.  Dr. Wang currently serves as co-Director of the ACR Education Center Breast MRI Course and is a member of the ACR BI-RADS MRI Subcommittee. Her research interests include breast MRI and breast cancer screening. Michael Cohen, MD, FACR, FSBI  The University of Texas Medical Branch Galveston, TX, USA Michael Cohen, MD, FACR, FSBI is an Emory University School of Medicine Professor Emeritus and past Director of the Emory Division of Breast Imaging. He now is a member of the breast imaging division at the University of Texas Medical Branch. His research interests center on high risk lesions of the breast, their diagnosis, and importantly, their management. Stamatia V. Destounis, MD, FACR, FSBI, FAIUM Managing Partner, Elizabeth Wende Breast Care Rochester, NY, USA Stamatia Destounis, MD, FACR, FSBI, FAIUM, is a practicing Radiologist and Managing Partner at Elizabeth Wende Breast Care. Dr. Destounis is Chair of the ACR Breast Commission and sits on several ACR committees and panels. She serves as a reviewer for several peer-review journals and is an ACR senior Breast Ultrasound and MRI accreditation reviewer. Dr. Destounis is the immediate past Chair of the Breast ACR Accreditation Committee. She has served on several committees for SBI and is currently a member of the Communication Task Force, and the Research and Education Task Force. Dr. Destounis is actively involved with research, acting as the PI on several clinical trials conducted at her practice and nationally and internationally. Her personal research interests include digital breast tomosynthesis, breast density, risk and genetics, and she has published numerous peer-reviewed articles and book chapters throughout her career on these topics. Dr. Destounis is the Breast Editor for Academic Radiology and Journal of Ultrasound and Medicine . Sarah (Sally) Friedewald, MD, FACR, FSBI Northwestern University Feinberg School of Medicine  Chicago, IL, USA Sarah M. Friedewald, MD, FACR,FSBI is the Vice Chair for Clinical Operations, Division Chief of Breast and Women’s imaging and Associate Professor in the Department of Radiology at Northwestern University, Feinberg School of Medicine. She is also Medical Director of the Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital. Dr. Friedewald received her medical degree from Columbia University, College of Physicians and Surgeons. After a surgical internship, she attended the diagnostic radiology residency program at the Johns Hopkins Hospital. She subsequently completed a fellowship in women’s imaging at the Hospital of the University of Pennsylvania. Dr. Friedewald is actively involved in multicenter trials evaluating the performance of digital breast tomosynthesis (DBT), was first author in a large study demonstrating the benefits of DBT in the Journal of the American Medical Association (JAMA), and teaches both nationally and internationally on this topic. She is on several leadership committees with the American College of Radiology, is a member of the Commission on Breast Imaging and is on the Executive Committees of the National Accreditation Program for Breast Centers (NAPBC) and the Commission on Cancer (CoC).  Lars J. Grimm, MD, MHS, FSBI Duke University Medical Center Durham, NC, USA Lars Grimm, MD, MHS, FSBI, is an Associate Professor in the Department of Radiology at Duke University Medical Center.  He completed his undergraduate degree in Geological and Environmental Sciences at Stanford University and then his Medical Degree and Master’s in Health Science at Yale University.  His internship, residency, and fellowship were at Duke University where he also served as Chief Resident.  He is a Fellow of the Society of Breast Imaging and currently the Chair of the SBI Patient Care and Delivery Committee and the ACR’s National Mammography Database.  Lars’ primary research interests are active surveillance for DCIS, health services research, AI/radiomics, and gender/racial inequality in residency recruitment.  He has received grant from the AUR, NIH, DOD, Alliance, and ECOG-ACRIN and published over 130 manuscripts.  He is currently PI on an R01 studying the natural history of DCIS to improve diagnosis and treatment decision making.  Lars is a Deputy Editor at  JMRI  and Assistant Editor at  JACR . Susan Lester, MD, PhD Brigham and Women’s Hospital Boston, MA, USA Susan Lester, MD, PhD, received her PhD in genetics at the University of Wisconsin and her MD from Harvard Medical School. She trained in pathology at Brigham and Women’s Hospital in Boston and was Chief of Breast Pathology Services for over 20 years. After the first image guided core needle biopsy was performed at BWH in 1992, she helped organize a radiologic/pathologic correlation conference which she continues to support along with her breast imaging colleagues. She was the chairperson of the College of American Pathology breast cancer review panel during the development of the first standardized reporting protocol for DCIS as well as a major revision of the invasive cancer protocol. She has served on committees for the CAP, the American Joint Committee on Cancer, and the World Health Organization. Dr. Lester is well known for her books, the Manual of Surgical Pathology and Diagnostic Pathology: Breast , as well as numerous book chapters and original research articles. Vilert Loving, MD, FSBI, MMM Banner MD Anderson Cancer Center Phoenix, AZ, USA Vilert Loving, MD, MMM, FSBI serves as the Chief of Breast Imaging and Co-Director of the Breast Cancer Multidisciplinary Program at Banner MD Anderson Cancer Center in Phoenix, Arizona. Dr. Loving is an enduring champion for high quality healthcare delivery and has led numerous interdisciplinary teams to tackle organization-wide healthcare quality and process improvement initiatives. He is an active member of multiple local and national breast cancer and radiology professional committees. Dr. Loving’s research interests include optimizing breast cancer diagnosis and building high-value, collaborative healthcare teams. Habib Rahbar, MD, FSBI University of Washington School of Medicine Seattle, WA, USA Habib Rahbar, MD, FSBI, is a Professor of Radiology in the Breast Imaging Section at the University of Washington (UW) School of Medicine/Fred Hutchinson Cancer Center and Vice Chair of Clinical Operations for the UW Department of Radiology. Dr. Rahbar completed his undergraduate studies at the University of Pennsylvania and received his medical degree from the University of Michigan. He completed his radiology residency and fellowship training at UW in Seattle. Dr. Rahbar is a Fellow of the Society of Breast Imaging and the Society of Breast MRI. He is the co-director of the UW Quantitative Breast Imaging Lab and has had multiple NCI-funded R01s studying the use of MRI to characterize the biologic risk of DCIS. Dr. Rahbar is actively involved in multiple local and national breast imaging research trials, is active in ECOG-ACRIN co-chairing the Radiomics Working Group, and is a member of the Breast Oncology Localized Disease (BOLD) Taskforce within the NCI Breast Cancer Steering Committee. Jean Seely, MDCM, FRCPC, FSBI University of Ottawa Ottawa, ON, Canada Jean Seely, MDCM, FRCPC, FSBI, is Professor of Medicine in the Faculty of Radiology at the University of Ottawa. She is a Fellow of the Society of Breast Imaging. She is Head of the Breast Imaging Section at the Ottawa Hospital, and the Regional Breast Imaging Lead for the Ontario Breast Screening Program in Champlain region. Jean is an Executive Board member of the Canadian Association of Radiologists' Breast Imaging Working group and the CAR Mammography Accreditation Program. She sits on the Editorial Board of the Canadian Association of Radiologists Journal and Journal of Breast Imaging . Her commitment is to reduce the mortality and morbidity of breast cancer and provide high quality breast imaging nationally and internationally. She is President and Chair of the Canadian Society of Breast Imaging. Her research interests include Breast MRI, breast cancer screening, quality indicators and patient experience. Martin Yaffe, PhD, FSBI, CM, FRSC University of Toronto Toronto, ON, Canada Martin Yaffe, PhD, FSBI, CM, FRSC, received a PhD in Medical Biophysics from The University of Toronto in 1978. Since that time his research has been almost exclusively focused on the use of medical imaging for detection, diagnosis, risk prediction and monitoring of response to treatment for breast cancer. His research team made major contributions to the development of digital mammography and he was part of the leadership team in the DMIST trial. He is also one of the principal investigators of the TMIST trial of breast tomosynthesis. He has also developed methods for quantitative measurement of breast density and, working with epidemiologist Dr. Norman Boyd, applied them in numerous studies of the etiology and possible prevention of breast cancer. He is very interested in the optimization of breast screening and has approached this problem through computer modeling which has included cost-effectiveness analysis. Most recently he has been working on methods in digital pathology for improving the characterization of breast cancer to allow more precision therapy. For his achievements, he was awarded the Order of Canada (Canada's highest civilian honor) in 2015 and an honorary doctorate from The University of Manitoba in 2018. International Advisory Board Katja pinker-domenig, md, phd, ebbi, fismrm [email protected] associate editor for international affairs chair, international advisory board memorial sloan kettering cancer center new york, ny, usa. Katja Pinker-Domenig, MD, PhD, EBBI, FISMRM, is Member at Memorial Sloan Kettering Cancer Center, Attending Radiologist at Memorial Hospital for Cancer and Allied Diseases, and Professor of Radiology, Weill Medical College of Cornell University, New York, USA. She is the Director of Research and Director of Breast MRI, Breast Imaging Service/Department of Radiology at the Memorial Sloan-Kettering Cancer Center. She is Affiliated Faculty at the Department of Scientific Computing at Florida State University, Tallahassee, USA, and Research Associate at the Department of Radiology at the Medical University of Vienna, Vienna, Austria. She is an expert in translational and clinical breast and oncologic gender imaging. Her research interests focus on advanced breast imaging with high resolution MRI using multiple advanced MRI parameters, hybrid imaging (PET)/MRI with specific tracers and the application of AI in oncologic imaging to develop imaging biomarkers for precision medicine. She has published more than 200 peer-reviewed papers in breast and oncologic imaging. Jung Min Chang, MD, PhD Seoul National University Seoul, Republic of Korea Jung Min Chang, MD, PhD, is a professor at the Breast Imaging section of the Department of Radiology at Seoul National University Hospital and Seoul National University College of Medicine. She is an internationally recognized researcher in breast imaging. Dr. Chang has more than 160 original research abstracts and publications. She conducted research on a wide range of topics, with a particular focus on multimodality breast cancer screening. She is currently an associate editor of Radiology , the secretary general of the Korean Society of Breast Imaging, and the chair of the public relations committee of the Korean Society of Ultrasound in Medicine. She was the section editor of Ultrasonography , and chair of the scientific program committee of the Korean Society of Breast Imaging. Fiona Gilbert, MBChB, DMRD, FRCR, FRCPS, FRCP, FACR, FRSE, FMedSci University of Cambridge Cambridge, UK Fiona Gilbert, MBChB, DMRD, FRCR, FRCPS, FRCP, FACR, FRSE, FMedSci, is Professor of Radiology and Head of Department of Radiology at the University of Cambridge, UK. Professor Gilbert graduated in medicine from the University of Glasgow, trained in Radiology in Aberdeen and was appointed to the Chair of Radiology at the University of Aberdeen in 1996 moving to the Chair of Radiology in Cambridge in 2011. She works clinically in Cambridge University Hospitals (Addenbrookes) in the breast unit and is part of the Cambridge Breast Unit which delivers screening to Cambridge & Huntingdon. Her research is focused on imaging techniques relating to breast cancer and oncology.  Previously she has evaluated digital breast tomosynthesis and computer aided detection in the breast screening program. She undertakes research in risk adapted stratified breast screening using abbreviated MRI, tomosynthesis, whole breast ultrasound and contrast enhanced mammography. Since 2012 Professor Gilbert has been awarded fifteen competitive grants worth over £20M. She was a previous associate editor of Clinical Radiology . Professor Gilbert has 250 peer reviewed publications, 5 book chapters, and numerous conference abstracts. She is a regular speaker at international Radiology conferences in Chicago and Vienna and was awarded Honorary membership of Radiological Society of North America in 2019, Honorary fellowship of the American College of Radiologists, the Gold Medal from the European Society of Radiology and fellowship of the Royal Society of Edinburgh in 2021, and fellowship of the Academy of Medical Sciences. She is immediate past President of the European Society of Breast Imaging. Special Consultants to the Editor Mark helvie, md, facr, fsbi university of michigan health system ann arbor, mi, usa . Mark Helvie, MD, FACR, FSBI, is Professor Emeritus of Radiology at the University of Michigan Health System. He is a Fellow in the Society of Breast Imaging, a Fellow in the American College of Radiology, and recent past Vice Chair of the National Comprehensive Cancer Network (NCCN) Breast Cancer Screening & Diagnosis Panel. He is board certified in Radiology and Internal Medicine. His major research is in the field of Breast Imaging including screening, tomosynthesis, computer-aided diagnosis (CAD), ultrasound (USN), and magnetic resonance imaging (MRI). Dr. Helvie has published over 250 peer-reviewed papers and has been awarded many grants. John Lewin, MD, FACR, FSBI Women’s Imaging Center  Denver, CO, USA  John Lewin, MD, FACR, FSBI, is Associate Professor and Division Chief of Breast Imaging in the Department of Radiology and Biomedical Imaging at the Yale School of Medicine. Dr. Lewin's career has included positions in both academic medicine and private practice and has encompassed clinical care, research and teaching in all aspects of breast imaging.  His research has focused on technology development and evaluation, particularly digital mammography and contrast-enhanced mammography.   Early in his career, while at the University of Colorado, using one of the first prototype devices, he conducted the first large clinical trial comparing digital mammography to film mammography for screening. In 1999 he began studying the use of intravenous contrast with digital mammography. This work led to the development and clinical demonstration of dual-energy contrast enhanced mammography (CEM). Dr. Lewin continues to study both the technical and clinical aspects of CEM.  One of his current focuses is on tumor ablation. Elizabeth Morris, MD, FACR, FSBI, FISMRM  University of California, Davis, School of Medicine Sacramento, CA, USA Elizabeth Morris, MD, FACR, FSBI, FISMRM, is Professor and Chair of Radiology at the University of California, Davis (UCD) School of Medicine. Dr. Morris graduated  summa cum laude  from UCD in biochemistry and received her medical degree from the University of California, San Francisco. She completed her residency at Weill Cornell Medical College and a body/breast imaging fellowship at Memorial Sloan Kettering Cancer Center where she remained on faculty until December 2020 where she was the Chief of the Breast Imaging Service and Larry Norton Endowed Chair. Dr. Morris is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI), and International Society of MR in Medicine (ISMRM) and is past president of the SBI. She is the inaugural Equity Diversity & Inclusion officer of the ISMRM and co-chair of the Women of ISMRM.  Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 230 papers, 40 chapters, and 5 books about breast disease with an emphasis on the use of MRI. She had lectured widely both nationally and internationally at over 320 conferences. She has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. She has authored the book  Breast MRI: Diagnosis & Intervention . Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response. Dana Smetherman, MD, MPH, MBA, FACR, FSBI Ochsner Medical Center New Orleans, LA, USA Dana Smetherman, MD, MPH, MBA, FACR, FSBI, is Chair of the Department of Radiology and Associate Medical Director for the Medical Specialties at Ochsner Medical Center – New Orleans. Dr. Smetherman is a breast radiologist and has served as chair of the Breast Commission of the American College of Radiology (ACR). She is currently the Secretary/Treasurer of the ACR and is a member of the organization’s Board of Chancellors. For many years, Dr. Smetherman was the Section Head for Breast Imaging at Ochsner Health, where she also served on the Board of Directors and as Chair of the Medical Advisory Committee. She has served as President of the Radiological Society of Louisiana, ACR Councilor from Louisiana, Board Member for the National Accrediting Program for Breast Centers of the American College of Surgeons, Chair of the Technical Exhibits Committee of the Radiological Society of North America, CPT Advisor and Alternate Advisor for the American Roentgen Ray Society, and Chair of the Breast Economics Committee of the ACR. Dr. Smetherman is a fellow of both the American College of Radiology and the Society of Breast Imaging and has given numerous presentations and has multiple publications in the areas of breast imaging and health care economics. Past Editors Wendy b. demartini, md, fsbi stanford university school of medicine stanford, ca, usa, jennifer a. harvey, md, facr, fsbi university of rochester school of medicine and dentistry rochester, ny, usa. Recommend to your Librarian Journals Career Network Affiliations Online ISSN 2631-6129 Print ISSN 2631-6110 Copyright © 2024 Society of Breast Imaging About Oxford Academic Publish journals with us University press partners What we publish New features   Open access Institutional account management Rights and permissions Get help with access Accessibility Advertising Media enquiries Oxford University Press Oxford Languages University of Oxford Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide Copyright © 2024 Oxford University Press Cookie settings Cookie policy Privacy policy Legal notice This Feature Is Available To Subscribers Only Sign In or Create an Account This PDF is available to Subscribers Only For full access to this pdf, sign in to an existing account, or purchase an annual subscription. 394 IMAGES Breast Cancer Research and Treatment Referencing Guide · Breast Cancer (PDF) Cost-effective analyses in Breast Cancer Research and Treatment ⚡ Sample research paper on breast cancer. Sample Research Paper on Volumes and issues Editorial Board A Multidisciplinary Approach in Management of Breast Cancer: Case Study COMMENTS Cancer Research and Treatment Editorial Board: Open Access: Best Reviewer Awardees: Article Processing Charge ... Editor's Note on Recent Journal Impact Factor of Cancer Research and Treatment. Yong Chan Ahn. Cancer Res Treat. 2024;56(3):699-699. Published online ... Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study ... Where to Find Cancer Care Particularly with rare cancers, it's really important to find a top cancer center to get an opinion, says Dr. Diane Reidy-Lagunes, a medical oncologist and associate deputy physician-in-chief at ... Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose PURPOSE We tested the ability of [18F] fluorthanatrace (FTT), a radiolabeled analog of poly(ADP-ribose) polymerase (PARP)-1 inhibitors, to demonstrate target engagement on positron emission tomography (PET) scans from patients with newly diagnosed primary breast cancer receiving the PARP inhibitor (PARPi) talazoparib. METHODS Seven patients with germline BRCA1/2 pathogenic variants underwent ... Editors Breast Cancer Research and Treatment. Editors. Breast Cancer Research and Treatment. Publishing model: Hybrid. Submit your manuscript. Back to overview; Editorial board; Aims and scope; Editors. Editor-in-Chief William J. Gradishar, MD Northwestern University, Feinberg School of Medicine, Chicago, IL, USA Editorial Board Editorial Board Roger A'Hern, MD, Institute of Cancer Research, UK Hans-Olov Adami, PhD, Harvard School of Public Health, USA Craig D Allred, PhD, Washington University School of Medicine, USA Steven M Anderson, PhD, University of Colorado, USA Fabrice Andre, PhD, Institut Gustave Roussy, France Carlos Arteaga, MD, Vanderbilt University, USA Home Editorial board; Aims and scope; Overview. Breast Cancer Research and Treatment is a comprehensive forum dedicated to all aspects of breast cancer research. The journal's focus spans across various disciplines including surgery, radiotherapy, medical oncology, endocrinology, epidemiology, immunology and cell biology. ... Volume 206, Issue 2 Breast Cancer Research and Treatment. Publishing model: Hybrid. Submit your manuscript. Back to overview; Editorial board; Aims and scope; Search all Breast Cancer Research and Treatment articles Volume 206, Issue 2 July 2024. 21 articles in this issue Breast Cancer Research and Treatment He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee. Editorial Board: Breast Cancer: Basic and Clinical Research: Sage Journals Wayne State University School of Medicine, Detroit, Michigan, USA. Valerie Marie Weaver PhD. University of California, San Francisco, CA, USA. Ray-Chang Wu PhD. George Washington University Medical Center, Washington, DC, USA. The editorial board of Breast Cancer: Basic and Clinical Research. Editorial Editorial. It is indeed an honor and privilege to assume the role of Editor-in-Chief for Breast Cancer Research and Treatment (BCRT). The baton being passed by Marc Lippman to me is truly humbling as he so ably guided the journal for nearly three decades. I am now just starting to appreciate the scope of work that he guided through all those years. Submission guidelines Breast Cancer Res Treat 100(2):229-235). Failure to do so will result in the manuscript being returned to the author without peer review, as outlined by the editors of Breast Cancer Research and Treatment : Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. About the Editors Dr. Larry Norton is a board-certified medical oncologist with broad interests in cancer prevention, diagnosis and treatment. His research concerns the basic biology of cancer, the mathematics of ... Cancer Research and Treatment Editorial Board: Open Access: Best Reviewer Awardees ... Most Read Articles: Most Cited Articles Cancer Research and Treatment: Search: Author Index . ORIGINAL ARTICLE 2024 January ... Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with ... Editorial board All members of the Editorial Board have identified their affiliated institutions or organizations, along with the corresponding country or geographic region. Elsevier remains neutral with regard to any jurisdictional claims. Read the latest articles of The Breast at ScienceDirect.com, Elsevier's leading platform of peer-reviewed scholarly ... Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise We are experiencing an amazing era of advances in the diagnosis and treatment of breast cancer, with the discovery of novel actionable biomarkers (e.g., programmed death-ligand 1 (PD-L1), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), mismatch repair) and the re-discovery of traditional and established ones, particularly for HER2 (low expression/mutations ... Submission guidelines Breast Cancer Research is the highest ranking breast cancer-specific title in the top quartile of oncology journals worldwide. ... Editorial Board; Manuscript editing services ... SCImago Journal Rank (SJR): 2.578 Speed 2023 Submission to first editorial decision (median days): 14 Submission to acceptance (median days): 129 Usage 2023 Downloads ... About Aims and scope. Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis ... Editorial board All members of the Editorial Board have identified their affiliated institutions or organizations, along with the corresponding country or geographic region. Elsevier remains neutral with regard to any jurisdictional claims. Read the latest articles of Clinical Breast Cancer at ScienceDirect.com, Elsevier's leading platform of peer-reviewed ... Editors Editors | Cancer Research | American Association for Cancer Research .container { display: flex; flex-direction: row; justify-content: flex-start; } .column {width: 250px; margin-right: 40px;} /* For devices smaller than 650px */ @media (max-width: 650px) { .container { flex-direction: column; } } h2,h3{margin-bottom: 2px;} Editorial Board   Editor-in-Chief Christine A. Iacobuzio-Donahue ... Home page Aims and scope. Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Open access research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis ... Cancer UC San Diego, San Diego, California. Dr. Patel joined Cancer as a Social Media Editor in July 2024 while also serving as the journal's Developmental Therapeutics Section Editor. Dr. Patel's social media interests include the dissemination of the latest clinical research findings focused on improving patients' quality of life. Breast Cancer: Basic and Clinical Research: Sage Journals Breast Cancer: Basic and Clinical Research is an international, peer-reviewed, open access journal that covers all aspects of research and treatment of breast cancer. The journal aims to promote understanding of breast cancer biology and … | View full journal description. This journal is a member of the Committee on Publication Ethics (COPE). Editorial Board Editorial Board Interim Editor-In-Chief Jay A. Baker, MD, FACR, FSBI [email protected] ... risk prediction and monitoring of response to treatment for breast cancer. His research team made major contributions to the development of digital mammography and he was part of the leadership team in the DMIST trial. He is also one of the principal ... Learn about Breast Cancer: Targets and Therapy Breast Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on breast cancer, basic and translational research, clinical trials and treatment. The latter includes outcome studies that incorporate preventative and integrated treatment strategies for enhanced survival, and quality of life for cancer ... assignment business plan case study course work essay report research paper speech term paper thesis